Groesbeck Investment Management Corp NJ lessened its position in Shire PLC (NASDAQ:SHPG) by 18.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,757 shares of the biopharmaceutical company’s stock after selling 408 shares during the period. Groesbeck Investment Management Corp NJ’s holdings in Shire were worth $273,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Seizert Capital Partners LLC increased its holdings in shares of Shire by 13.3% in the 3rd quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock worth $1,652,000 after acquiring an additional 1,267 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Shire by 2.9% in the 3rd quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock worth $8,793,000 after acquiring an additional 1,619 shares during the period. Morningstar Investment Services LLC increased its holdings in shares of Shire by 53.0% in the 3rd quarter. Morningstar Investment Services LLC now owns 25,882 shares of the biopharmaceutical company’s stock worth $3,964,000 after acquiring an additional 8,969 shares during the period. Trillium Asset Management LLC increased its holdings in shares of Shire by 2.3% in the 3rd quarter. Trillium Asset Management LLC now owns 49,083 shares of the biopharmaceutical company’s stock worth $7,517,000 after acquiring an additional 1,082 shares during the period. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Shire in the 3rd quarter worth about $4,338,000. 20.31% of the stock is currently owned by institutional investors and hedge funds.

Shire PLC (NASDAQ:SHPG) opened at $127.43 on Friday. The stock has a market cap of $37,971.00, a PE ratio of 23.86, a P/E/G ratio of 0.68 and a beta of 1.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire PLC has a 12-month low of $123.73 and a 12-month high of $192.15.

Shire (NASDAQ:SHPG) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.86 by ($0.49). Shire had a net margin of 10.95% and a return on equity of 14.41%. equities analysts forecast that Shire PLC will post 15 earnings per share for the current fiscal year.

A number of research firms recently weighed in on SHPG. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a report on Tuesday. Royal Bank of Canada set a $192.00 target price on shares of Shire and gave the company a “buy” rating in a research report on Monday, February 5th. Bank of America increased their target price on shares of Shire from $236.00 to $237.00 and gave the company a “buy” rating in a research report on Monday, February 5th. ValuEngine lowered shares of Shire from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub lowered shares of Shire from a “sell” rating to a “strong sell” rating in a research report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. Shire presently has an average rating of “Hold” and an average price target of $212.50.

TRADEMARK VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2018/02/10/groesbeck-investment-management-corp-nj-has-273000-position-in-shire-plc-shpg.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.